LIVE
JNJ
Johnson & Johnson · Healthcare
$228.39
-0.70% this month
VERSUS
⟷
COMPARE
ABBV
AbbVie Inc. · Healthcare
$216.49
+1.28% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
JNJ
1
ABBV
4
Comparison scoreboard
ABBV LEADS 4/5AI Score
JNJ 48.7
ABBV ✓52.0
1Y Return
JNJ ✓+49.88%
ABBV +16.72%
Fwd P/E
JNJ 18.94
ABBV ✓14.01
Target Up.
JNJ +4.98%
ABBV ✓+11.34%
Op. Margin
JNJ 27.41%
ABBV ✓32.16%
Metrics last refreshed: 6/20/2026
Quick take
JNJ vs ABBV Stock Comparison: AI Score, Valuation, Performance and Upside
Johnson & Johnson and AbbVie are both large-cap pharmaceutical companies with strong dividend histories facing near-term headwinds from biosimilar competition. J&J faces Stelara biosimilar pressure but has MedTech diversification and Darzalex/Carvykti oncology upside. AbbVie faces Humira biosimilar devastation but has Skyrizi/Rinvoq immunology replacements growing rapidly and Botox as a durable aesthetics franchise. Both are income-oriented large-cap healthcare holdings with different pipeline replacement execution stories.
JNJ vs ABBV is diversified pharma-plus-medical-devices with oncology growth (Darzalex, Carvykti) offsetting Stelara biosimilar headwind (J&J) versus pure pharma immunology specialist replacing $20B Humira revenue with Skyrizi/Rinvoq while Botox provides aesthetics stability (AbbVie) — both navigating major biosimilar transitions with strong pipeline replacements.
Live analysis · updated 6/20/2026
ABBV holds the edge across 4 of 5 key metrics in this comparison. JNJ has delivered stronger 1-year price return (+49.88% vs +16.72%), though ABBV trades at the lower forward P/E (14.01x vs 18.94x). ABBV leads on both revenue growth (12.40%) and operating margin (32.16%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ABBV (+11.34%) than for JNJ (+4.98%).
Normalized 1Y performance
JNJ
ABBV
Recent returns
JNJ
ABBV
Analyst price targets & sentiment
JNJ · 23 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.3/5.0)
Price target range
analyst low$150.00
analyst mean$252.87
current price$228.39
+5.0% upside to analyst mean
ABBV · 27 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.0/5.0)
Price target range
analyst low$170.00
analyst mean$253.55
current price$216.49
+11.3% upside to analyst mean
Who should consider this stock?
JNJ may suit investors who:
- →prefer diversified healthcare with pharmaceutical and medical device combination reducing single-drug patent cliff exposure relative to pure pharma companies
- →value Darzalex and Carvykti oncology growth as premium-priced products in multiple myeloma with expanding market opportunity
- →want healthcare blue-chip with 60+ consecutive dividend increases — one of the most reliable dividend growth stocks in the market
- →are comfortable with Stelara biosimilar revenue headwind, ongoing talc litigation uncertainty, and MedTech competitive intensity
ABBV may suit investors who:
- →prefer immunology specialist with Skyrizi/Rinvoq replacing Humira at potentially greater combined peak revenue by 2027
- →value AbbVie's Botox aesthetics franchise as a uniquely brand-protected premium product with limited biosimilar risk in the near term
- →want the highest current dividend yield among large-cap pharma — AbbVie's commitment to dividend growth is very strong
- →are comfortable with Humira revenue decline magnitude through 2026, Skyrizi/Rinvoq immunology competition from peers, and aesthetics segment cyclicality
Performance & AI score
| Metric | JNJ | ABBV |
|---|---|---|
| AI score | 48.7 | 52.0 |
| AI rank | #544 | #346 |
| Latest close | $228.39 | $216.49 |
| 1M return | -0.70% | +1.28% |
| 6M return | +8.59% | -3.49% |
| 1Y return | +49.88% | +16.72% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | JNJ | ABBV |
|---|---|---|
| 1Y ago | $15.15K (+51.5%) started 2025-06-18 | $11.67K (+16.7%) started 2025-06-18 |
| 5Y ago | $17.38K (+73.8%) started 2021-06-21 | $26.07K (+160.7%) started 2021-06-21 |
| 10Y ago | $32.67K (+226.7%) started 2016-06-20 | $83.39K (+733.9%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | JNJ | ABBV |
|---|---|---|
| Market cap | $579.83B | $402.35B |
| Trailing P/E | 27.94 | 111.09 |
| Forward P/E | 18.94 | 14.01 |
| Price/Sales | 4.18 | 5.85 |
| EV/Revenue | 6.36 | 7.42 |
| Analyst target | $252.87 | $253.55 |
| Target upside | +4.98% | +11.34% |
Growth, profitability & risk
| Metric | JNJ | ABBV |
|---|---|---|
| Revenue growth | 9.90% | 12.40% |
| Earnings growth | -52.90% | -46.20% |
| EPS growth | -52.90% | -46.20% |
| FCF margin | +12.98% | +33.13% |
| Operating margin | 27.41% | 32.16% |
| Profit margin | 21.83% | 5.79% |
| ROIC proxy | 26.42% | 6225.00% |
| Return on equity | 26.42% | 6225.00% |
| Dividend yield | 2.23% | 3.04% |
| Beta | 0.26 | 0.31 |
| Debt/equity | 67.73 | 4789.60 |
| Current ratio | 1.02 | 0.80 |
| Quick ratio | 0.69 | 0.52 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
JNJ max drawdown10.96%
ABBV max drawdown19.23%
JNJ max wkly drop5.81%
ABBV max wkly drop8.49%
5Y risk snapshot
JNJ max drawdown18.41%
ABBV max drawdown21.92%
JNJ max wkly drop9.18%
ABBV max wkly drop17.30%
10Y risk snapshot
JNJ max drawdown27.37%
ABBV max drawdown45.09%
JNJ max wkly drop13.25%
ABBV max wkly drop19.39%
Performance metrics by period
| Period | Metric | JNJ | ABBV |
|---|---|---|---|
| 1Y | Growth | +51.52% | +16.71% |
| CAGR | +51.61% | +16.74% | |
| Sharpe ratio | 2.26 | 0.57 | |
| Max drawdown | 10.96% | 19.23% | |
| Max daily drop | 2.48% | 5.20% | |
| Max wkly drop | 5.81% | 8.49% | |
| 5Y | Growth | +55.21% | +120.43% |
| CAGR | +9.20% | +17.16% | |
| Sharpe ratio | 0.34 | 0.61 | |
| Max drawdown | 18.41% | 21.92% | |
| Max daily drop | 7.59% | 12.57% | |
| Max wkly drop | 9.18% | 17.30% | |
| 10Y | Growth | +149.24% | +426.67% |
| CAGR | +9.57% | +18.09% | |
| Sharpe ratio | 0.34 | 0.60 | |
| Max drawdown | 27.37% | 45.09% | |
| Max daily drop | 10.04% | 16.25% | |
| Max wkly drop | 13.25% | 19.39% |
Business comparison
| Category | JNJ | ABBV |
|---|---|---|
| Company | Johnson & Johnson | AbbVie Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Johnson & Johnson is one of the world's largest healthcare companies, operating two segments: Innovative Medicine (pharmaceutical drugs including Stelara, Darzalex, Tremfya, Carvykti) and MedTech (surgical devices, orthopedics, cardiovascular equipment). J&J spun off its consumer health segment (Kenvue) in 2023, focusing on higher-margin pharmaceutical and medical device businesses. J&J's pharmaceutical pipeline has notable oncology (Darzalex, Carvykti CAR-T) and immunology (Tremfya) programs. | AbbVie is the world's top-selling drug by revenue via Humira (adalimumab) — an anti-inflammatory biologic that generated $20B+ at peak. Humira biosimilar competition began in the US in 2023, creating a significant revenue headwind. AbbVie has invested heavily in replacing Humira through Skyrizi (risankizumab for psoriasis and IBD) and Rinvoq (upadacitinib for rheumatoid arthritis, atopic dermatitis) — both are growing rapidly. AbbVie's Allergan acquisition added Botox, fillers, and aesthetics to its portfolio. |
| Investor focus | Investors track Darzalex (multiple myeloma) and Carvykti (CAR-T cell therapy) sales growth, MedTech procedure volume recovery, Innovative Medicine pipeline milestones, and Stelara biosimilar revenue headwind management. | Investors track Skyrizi and Rinvoq combined sales growth vs Humira biosimilar revenue decline, Botox (neurotoxin) and aesthetics revenue, and oncology pipeline progress (NaviNe, epkinly). |
JNJ strengths
- →Most diversified large-cap pharma with pharmaceutical + medical device combination — device revenue is less patent-cliff dependent than drug revenue
- →Darzalex is one of the world's best-selling oncology drugs — still growing and expanding into earlier lines of multiple myeloma treatment
- →Carvykti CAR-T cell therapy represents next-generation oncology — manufacturing capacity expansion is enabling rapid revenue growth in this premium-priced treatment
ABBV strengths
- →Skyrizi and Rinvoq are both best-in-class immunology drugs growing 40–50% annually — AbbVie's internal forecasts project these drugs replacing and exceeding Humira's peak revenue by 2027
- →Botox neurotoxin is the global brand standard in aesthetics and medical neurotoxin — monopoly-like position in premium aesthetics with limited biosimilar risk
- →AbbVie's immunology expertise after decades of Humira development creates a durable pipeline in immune-mediated diseases where it has deep clinical and regulatory expertise
Risks to watch — JNJ
- →Stelara (formerly $10B+ revenue drug) faces biosimilar competition beginning 2025 — this patent cliff represents a significant revenue headwind J&J must offset with pipeline launches
- →Talc liability litigation (baby powder lawsuits) remains an ongoing legal overhang with potential significant settlement costs
- →MedTech competitive intensity from Medtronic, Abbott, and Stryker in J&J's device segments
Risks to watch — ABBV
- →Humira biosimilar revenue decline is dramatic and rapid — managing the transition from Humira revenue to Skyrizi/Rinvoq is a multi-year earnings story
- →Skyrizi and Rinvoq competition from AstraZeneca, Pfizer, and Lilly in overlapping indications could limit pricing power in immunology
- →Aesthetics market cyclicality — Botox/filler revenues are more consumer-discretionary than pharmaceutical revenues and can slow in economic downturns
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →